CAS 1227634-69-6

Fórmula: C24H25N7

InChI: InChI=1S/C24H25N7/c1-15(2)31-14-28-21-23(26-9-8-17-13-27-20-7-5-4-6-19(17)20)29-22(30-24(21)31)18-10-16(3)11-25-12-18/h4-7,10-15,27H,8-9H2,1-3H3,(H,26,29,30)

Clave InChI: ABXIUYMKZDZUDC-UHFFFAOYSA-N

SMILES: CC1=CC(=CN=C1)C2=NC(=C3C(=N2)N(C=N3)C(C)C)NCCC4=CNC5=CC=CC=C54

GNF351

CAS: 1227634-69-6

GNF351: Full AHR antagonist, inhibits DRE-dependent/independent activity, low toxicity, binds AHR (IC50: 62 nM).

Fórmula: C₂₄H₂₅N₇

Pureza: 98.43%

Forma y color: Solid

Peso molecular: 411.5022

Ref: TM-T15410

GNF351

CAS: 1227634-69-6

GNF351

Fórmula: C₂₄H₂₅N₇

Pureza: ≥98%

Peso molecular: 411.5

Ref: 54-BUP08737

GNF351

CAS: 1227634-69-6

Fórmula: C₂₄H₂₅N₇

Pureza: 99%

Forma y color: Solid

Peso molecular: 411.5022

Ref: IN-DA01V3SA

GNF351

CAS: 1227634-69-6

N-(2-(1H-Indol-3-yl)ethyl)-9-isopropyl-2-(5-methylpyridin-3-yl)-9H-purin-6-amine

Fórmula: C₂₄H₂₅N₇

Pureza: 99%

Peso molecular: 411.5

Ref: IN-DG559177

GNF351

CAS: 1227634-69-6

GNF351 is a growth factor that is structurally related to epidermal growth factor. It is a basic fibroblast growth factor (bFGF) with the amino acid sequence of Val-Ala-Gly-Arg-Leu-Lys. GNF351 binds to cellular receptors, which then initiate signal transduction pathways in response to extracellular stimuli. The binding of GNF351 to these receptors has been shown to induce cell proliferation and differentiation, as well as stimulation of angiogenesis and wound healing. This drug can be used for the treatment of autoimmune diseases, inflammatory skin diseases, and cancer. Treatment with GNF351 has been shown to inhibit the growth of liver cells in culture after chronic exposure, suggesting it may have a hepatoprotective effect. The detection time for this drug is very short; it can be detected in the blood after only 4 hours following administration.

Fórmula: C₂₄H₂₅N₇

Pureza: Min. 95%

Peso molecular: 411.5 g/mol

Ref: 3D-CZB63469